Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2009;6(1):13–9.CrossRefPubMedCentralPubMed

Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Investig Dermatol. 2009;129(2):289–301.CrossRefPubMed

Maloney DG, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–66.PubMed

Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128(12):2745–7.CrossRefPubMed

Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5):394–403.CrossRefPubMed

Schmidt E, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503–8.CrossRefPubMed

McDonald V, Leandro M. Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol. 2009;146(3):233–46.CrossRefPubMed

Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999;58(1):79–88; discussion 89–90.CrossRefPubMed

Mouquet H, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Investig Dermatol. 2008;128(12):2859–69.CrossRefPubMed

Eming R, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.CrossRefPubMed

Horvath B, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–12.CrossRefPubMed

Le Roux-Villet C, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147:843–9.CrossRefPubMed

Schmidt E, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.CrossRefPubMed

Mercader P, et al. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2007;21(8):1141–2.CrossRefPubMed

Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.CrossRefPubMed

Rios-Fernandez R, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol. 2007;157(6):1271–3.CrossRefPubMed

Li WW, et al. Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris. Br J Dermatol. 2009;161(1):205–6.CrossRefPubMed

Matsukura S, et al. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol. 2012;148(6):734–9.CrossRefPubMed

Diab M, et al. Treatment of refractory pemphigus erythematosus with rituximab. Int J Dermatol. 2008;47(12):1317–8.CrossRefPubMed

Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47(3):292–4.CrossRefPubMed